Trials / Completed
CompletedNCT00780806
Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults
An Open-Label Safety And Blood Collection Study In Mnb Rlp2086 Vaccinated Healthy Adult Volunteers For Immunological Assay Development
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety of an investigational meningococcal B rLP2086 vaccine in adults and to obtain blood samples from immunized subjects for use in assay development.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | meningococcal B rLP2086 vaccine candidate | vaccine, 0.5 mL, 3 doses, 0 - 2 - 6 to 9 months |
| PROCEDURE | Blood draw | Blood draw |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2010-05-01
- Completion
- 2010-05-01
- First posted
- 2008-10-28
- Last updated
- 2011-08-23
Locations
3 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT00780806. Inclusion in this directory is not an endorsement.